Monoamine transporter inhibitors and substrates as treatments for stimulant abuse

Advances in Pharmacology

Volumn 69, Issue , 2014, Pages 129-176

  Howell, Leonard L ^a   Negus, S Stevens ^b  

^a EMORY UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Amphetamine; Cocaine; Dopamine; Drug discrimination; Monoamines; Neuroimaging; Nonhuman primates; Norepinephrine; Self administration; Serotonin

Indexed keywords

DRUGS USED IN THE TREATMENT OF ADDICTION; MONOAMINE DERIVATIVE; MONOAMINE TRANSPORTER INHIBITOR; MONOAMINE TRANSPORTER SUBSTRATE; PSYCHOSTIMULANT AGENT; UNCLASSIFIED DRUG;

ARTICLE; DRUG ABUSE; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG DESIGN; DRUG DISCRIMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG SELF ADMINISTRATION; HUMAN; INSTRUMENTAL CONDITIONING; MEDICAL LIABILITY; NEUROBIOLOGY; NONHUMAN; PRIORITY JOURNAL; REINFORCEMENT;

AMPHETAMINE; COCAINE; DOPAMINE; DRUG DISCRIMINATION; MONOAMINES; NEUROIMAGING; NONHUMAN PRIMATES; NOREPINEPHRINE; SELF-ADMINISTRATION; SEROTONIN;

ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; CITALOPRAM; COCAINE-RELATED DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MEMBRANE TRANSPORT PROTEINS; MORPHOLINES; SUBSTANCE-RELATED DISORDERS; SUBSTRATE SPECIFICITY; TREATMENT OUTCOME; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84893192123     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/B978-0-12-420118-7.00004-4     Document Type: Chapter

References (249)

1. Amara S.G., Kuhar M.J. Neurotransmitter transporters: Recent progress. Annual Review of Neuroscience 1993, 16:73-93.
2. American_Psychiatric_Association Diagnostic and statistical manual of mental disorders 2013, American Psychiatric Publishing, Arlington, VA. 5th ed.
3. Andersen M.L., Kessler E., Murnane K.S., McClung J.C., Tufik S., Howell L.L. Dopamine transporter-related effects of modafinil in rhesus monkeys. Psychopharmacology 2010, 210:439-448.
4. Anderson A.L., Reid M.S., Li S.H., Holmes T., Shemanski L., Slee A., et al. Modafinil for the treatment of cocaine dependence. Drug and Alcohol Dependence 2009, 104:133-139.
5. Arndt I.O., Dorozynsky L., Woody G.E., McLellan A.T., O'Brien C.P. Desipramine treatment of cocaine dependence in methadone-maintained patients. Archives of General Psychiatry 1992, 49:888-893.
6. Astier B., Van Bockstaele E.J., Aston-Jones G., Pieribone V.A. Anatomical evidence for multiple pathways leading from the rostral ventrolateral medulla (nucleus paragigantocellularis) to the locus coeruleus in rat. Neuroscience Letters 1990, 118:141-146.
7. Ator N.A., Griffiths R.R. Principles of drug abuse liability assessment in laboratory animals. Drug and Alcohol Dependence 2003, 70:S55-S72.
8. Baker D.A., Tran-Nguyen T.L., Fuchs R.A., Neisewander J.L. Influence of individual differences and chronic fluoxetine treatment on cocaine-seeking behavior in rats. Psychopharmacology 2001, 155:18-26.
9. Banks M.L., Blough B.E., Fennel T.R., Snyder R.W., Negus S.S. Effects of phendimetrazine treatment on cocaine vs food choice and extended-access cocaine consumption in rhesus monkeys. Neuropsychopharmacology 2013, 38:2698-2707.
10. Banks M.L., Blough B.E., Negus S.S. Effects of monoamine releasers with varying selectivity for releasing dopamine/norepinephrine versus serotonin on choice between cocaine and food in rhesus monkeys. Behavioural Pharmacology 2011, 22:824-836.
11. Banks M.L., Blough B.E., Negus S.S. Effects of 14-day treatment with the schedule III anorectic phendimetrazine on choice between cocaine and food in rhesus monkeys. Drug and Alcohol Dependence 2013, 131:204-213.
12. Banks M.L., Czoty P.W., Gage H.D., Bounds M.C., Garg P.K., Garg S., et al. Effects of cocaine and MDMA self-administration on serotonin transporter availability in monkeys. Neuropsychopharmacology 2008, 33:219-225.
13. Banks M.L., Negus S.S. Preclinical determinants of drug choice under concurrent schedules of drug self-administration. Advances in Pharmacological Sciences 2012, 2012:281768.
14. Barnes N.M., Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999, 38:1083-1152.
15. Barrett R.J., Caul W.F., Smith R. Withdrawal, tolerance, and sensitization to dopamine mediated interoceptive cues in rats trained on a three-lever drug-discrimination task. Pharmacology, Biochemistry and Behavior 2005, 81:1-8.
16. Bauer C.T., Banks M.L., Blough B.E., Negus S.S. Use of intracranial self-stimulation to evaluate abuse-related and abuse-limiting effects of monoamine releasers in rats. British Journal of Pharmacology 2013, 168:850-862.
17. Baumann M.H., Ayestas M.A., Dersch C.M., Brockington A., Rice K.C., Rothman R.B. Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: Therapeutic implications. Synapse 2000, 36:102-113.
18. Baumann M.H., Ayestas M.A., Partilla J.S., Sink J.R., Shulgin A.T., Daley P.F., et al. The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 2012, 37:1192-1203.
19. Baumann M.H., Rothman R.B. Alterations in serotonergic responsiveness during cocaine withdrawal in rats: Similarities to major depression in humans. Biological Psychiatry 1998, 44:578-591.
20. Bergman J., Kamien J.B., Spealman R.D. Antagonism of cocaine self-administration by selective dopamine D(1) and D(2) antagonists. Behavioural Pharmacology 1990, 1:355-363.
21. Bergman J., Madras B.K., Johnson S.E., Spealman R.D. Effects of cocaine and related drugs in nonhuman primates. III. Self-administration by squirrel monkeys. The Journal of Pharmacology and Experimental Therapeutics 1989, 251:150-155.
22. Biebuyck J. Pharmacology and therapeutic applications of cocaine. Anesthesiology 1990, 73:518-531.
23. Boulay D., Duterte-Boucher D., Leroux-Nicollet I., Naudon L., Costentin J. Locomotor sensitization and decrease in [3H]mazindol binding to the dopamine transporter in the nucleus accumbens are delayed after chronic treatments by GBR12783 or cocaine. The Journal of Pharmacology and Experimental Therapeutics 1996, 278:330-337.
24. Bradberry C.W. Acute and chronic dopamine dynamics in a nonhuman primate model of recreational cocaine use. The Journal of Neuroscience 2000, 20:7109-7115.
25. Burmeister J.J., Lungren E.M., Neisewander J.L. Effects of fluoxetine and d-fenfluramine on cocaine-seeking behavior in rats. Psychopharmacology 2003, 168:146-154.
26. Caine S.B., Koob G.F. Effects of dopamine D-1 and D-2 antagonists on cocaine self-administration under different schedules of reinforcement in the rat. The Journal of Pharmacology and Experimental Therapeutics 1994, 270:209-218.
27. Caine S.B., Negus S.S., Mello N.K., Bergman J. Effects of dopamine D1-like and D2-like agonists in rats trained to discriminate cocaine from saline: Influence of experimental history. Experimental and Clinical Psychopharmacology 2000, 8:404-414.
28. Campbell J.L., Thomas H.M., Gabrielli W., Liskow B.I., Powell B.J. Impact of desipramine or carbamazepine on patient retention in outpatient cocaine treatment: Preliminary findings. Journal of Addictive Diseases 1994, 13:191-199.
29. Carlezon W.A., Nestler E.J. Elevated levels of GluR1 in the midbrain: A trigger for sensitization to drugs of abuse?. Trends in Neurosciences 2002, 25:610-615.
30. Carpenter M.B., Sutin J. Human neuroanatomy 1983, Williams & Wilkins, Baltimore.
31. Carrasco G.A., Battaglia G. Withdrawal from a single exposure to cocaine increases 5-HT2A receptor and G protein function. Neuroreport 2007, 18:51-55.
32. Carrasco G.A., Van de Kar L.D., Sullivan N.R., Landry M., Garcia F., Muma N.A., et al. Cocaine-mediated supersensitivity of 5-HT2A receptors in hypothalamic paraventricular nucleus is a withdrawal-induced phenomenon. Neuroscience 2006, 143:7-13.
33. Carroll F.I., Howell L.L., Kuhar M.J. Pharmacotherapies for treatment of cocaine abuse: Preclinical aspects. Journal of Medicinal Chemistry 1999, 42:2721-2736.
34. Carroll M.E., Lac S.T., Asencio M., Kragh R. Fluoxetine reduces intravenous cocaine self-administration in rats. Pharmacology, Biochemistry and Behavior 1990, 35:237-244.
35. Carter L.P., Griffiths R.R. Principles of laboratory assessment of drug abuse liability and implications for clinical development. Drug and Alcohol Dependence 2009, 105(Suppl. 1):S14-S25.
36. Catterall W.A., Mackie K. Local anesthetics. The pharmacological basis of therapeutics 2005, 369-388. McGraw-Hill, New York. J.G. Hardman, L.E. Limbird (Eds.).
37. Chi L., Reith M.E. Substrate-induced trafficking of the dopamine transporter in heterologously expressing cells and in rat striatal synaptosomal preparations. The Journal of Pharmacology and Experimental Therapeutics 2003, 307:729-736.
38. Chiodo K.A., Lack C.M., Roberts D.C. Cocaine self-administration reinforced on a progressive ratio schedule decreases with continuous D-amphetamine treatment in rats. Psychopharmacology 2008, 200:465-473.
39. Claye L.H., Akunne H.C., Davis M.D., DeMattos S., Soliman K.F. Behavioral and neurochemical changes in the dopaminergic system after repeated cocaine administration. Molecular Neurobiology 1995, 11:55-66.
40. Colpaert F.C. Drug discrimination in neurobiology. Pharmacology, Biochemistry and Behavior 1999, 64:337-345.
41. Comer S.D., Ashworth J.B., Foltin R.W., Johanson C.E., Zacny J.P., Walsh S.L. The role of human drug self-administration procedures in the development of medications. Drug and Alcohol Dependence 2008, 96:1-15.
42. Comer S.D., Mogali S., Saccone P.A., Askalsky P., Martinez D., Walker E.A., et al. Effects of acute oral naltrexone on the subjective and physiological effects of oral d-amphetamine and smoked cocaine in cocaine abusers. Neuropsychopharmacology 2013, 38:2427-2438.
43. Corwin R.L., Woolverton W.L., Schuster C.R., Johanson C.E. Anorectics: Effects on food intake and self-administration in rhesus monkeys. Alcohol and Drug Research 1987, 7:351-361.
44. Cunningham K.A., Paris J.M., Goeders N.E. Chronic cocaine enhances serotonin autoregulation and serotonin uptake binding. Synapse 1992, 11:112-123.
45. Czoty P.W., Gage H.D., Nader M.A. PET imaging of striatal dopamine D2 receptors in nonhuman primates: Increases in availability produced by chronic raclopride treatment. Synapse 2005, 58:215-219.
46. Czoty P.W., Ginsburg B.C., Howell L.L. Serotonergic attenuation of the reinforcing and neurochemical effects of cocaine in squirrel monkeys. The Journal of Pharmacology and Experimental Therapeutics 2002, 300:831-837.
47. Czoty P.W., Martelle J.L., Garrett B.E., Nader M.A. Chronic d-amphetamine alters food-reinforced responding and cocaine self-administration under a progressive-ratio schedule in rhesus monkeys. FASEB Journal 2008, 22:713-714.
48. Czoty P.W., Martelle S.E., Gould R.W., Nader M.A. Effects of chronic methylphenidate on cocaine self-administration under a progressive-ratio schedule of reinforcement in rhesus monkeys. The Journal of Pharmacology and Experimental Therapeutics 2013, 345:374-382.
49. Czoty P.W., Morgan D., Shannon E.E., Gage H.D., Nader M.A. Characterization of dopamine D1 and D2 receptor function in socially housed cynomolgus monkeys self-administering cocaine. Psychopharmacology 2004, 174:381-388.
50. Czoty P.W., Reboussin B.A., Calhoun T.L., Nader S.H., Nader M.A. Long-term cocaine self-administration under fixed-ratio and second-order schedules in monkeys. Psychopharmacology 2007, 191:287-295.
51. Dackis C.A., Kampman K.M., Lynch K.G., Pettinati H.M., O'Brien C.P. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2005, 30:205-211.
52. Dackis C.A., Kampman K.M., Lynch K.G., Plebani J.G., Pettinati H.M., Sparkman T., et al. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Journal of Substance Abuse Treatment 2012, 43:303-312.
53. Dackis C.A., Lynch K.G., Yu E., Samaha F.F., Kampman K.M., Cornish J.W., et al. Modafinil and cocaine: A double-blind, placebo-controlled drug interaction study. Drug and Alcohol Dependence 2003, 70:29-37.
54. Daws L.C., Callaghan P.D., Moron J.A., Kahlig K.M., Shippenberg T.S., Javitch J.A., et al. Cocaine increases dopamine uptake and cell surface expression of dopamine transporters. Biochemical and Biophysical Research Communications 2002, 290:1545-1550.
55. Ding Y.S., Singhal T., Planeta-Wilson B., Gallezot J.D., Nabulsi N., Labaree D., et al. PET imaging of the effects of age and cocaine on the norepinephrine transporter in the human brain using (S, S)-[(11)C]O-methylreboxetine and HRRT. Synapse 2010, 64:30-38.
56. D'Mello G.D., Stolerman I.P. Comparison of the discriminative stimulus properties of cocaine and amphetamine in rats. British Journal of Pharmacology 1977, 61:415-422.
57. Do Carmo G.P., Mello N.K., Rice K.C., Folk J.E., Negus S.S. Effects of the selective delta opioid agonist SNC80 on cocaine- and food-maintained responding in rhesus monkeys. European Journal of Pharmacology 2006, 547:92-100.
58. Dwoskin L.P., Peris J., Yasuda R.P., Philpott K., Zahniser N.R. Repeated cocaine administration results in supersensitivity of striatal D-2 dopamine autoreceptors to pergolide. Life Sciences 1988, 42:255-262.
59. Epstein D.H., Preston K.L., Stewart J., Shaham Y. Toward a model of drug relapse: An assessment of the validity of the reinstatement procedure. Psychopharmacology 2006, 189:1-16.
60. Erickson J.D., Eiden L.E., Hoffman B.J. Expression cloning of a reserpine-sensitive vesicular monoamine transporter. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:10993-10997.
61. Ferster C.B., Skinner B.F. Schedules of reinforcement 1957, Appleton-Century-Crofts, New York.
62. Fischman M.W., Schuster C.R., Resnekov L., Shick J.F., Krasnegor N.A., Fennell W., et al. Cardiovascular and subjective effects of intravenous cocaine administration in humans. Archives of General Psychiatry 1976, 33:983-989.
63. Fleckenstein A.E., Gibb J.W., Hanson G.R. Differential effects of stimulants on monoaminergic transporters: Pharmacological consequences and implications for neurotoxicity. European Journal of Pharmacology 2000, 406:1-13.
64. Furman C.A., Chen R., Guptaroy B., Zhang M., Holz R.W., Gnegy M. Dopamine and amphetamine rapidly increase dopamine transporter trafficking to the surface: Live-cell imaging using total internal reflection fluorescence microscopy. The Journal of Neuroscience 2009, 29:3328-3336.
65. Gerber G.J., Stretch R. Drug-induced reinstatement of extinguished self-administration behavior in monkeys. Pharmacology, Biochemistry and Behavior 1975, 3:1055-1061.
66. Ginsburg B.C., Kimmel H.L., Carroll F.I., Goodman M.M., Howell L.L. Interaction of cocaine and dopamine transporter inhibitors on behavior and neurochemistry in monkeys. Pharmacology, Biochemistry and Behavior 2005, 80:481-491.
67. Glatz A.C., Ehrlich M., Bae R.S., Clarke M.J., Quinlan P.A., Brown E.C., et al. Inhibition of cocaine self-administration by fluoxetine or D-fenfluramine combined with phentermine. Pharmacology, Biochemistry and Behavior 2002, 71:197-204.
68. Glennon R.A., Young R. Drug discrimination: Applications to medicinal chemistry and drug studies 2011, John Wiley and Sons, Hoboken, NJ.
69. Glowa J.R., Fantegrossi W.E., Lewis D.B., Matecka D., Rice K.C., Rothman R.B. Sustained decrease in cocaine-maintained responding in rhesus monkeys with 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-hydroxy-3-phenylpropyl) piperazinyl decanoate, a long-acting ester derivative of GBR 12909. Journal of Medicinal Chemistry 1996, 39:4689-4691.
70. Glowa J.R., Wojnicki F.H., Matecka D., Bacher J.D. Effects of dopamine reuptake inhibitors on food- and cocaine-maintained responding: I. Dependence on unit dose of cocaine. Experimental and Clinical Psychopharmacology 1995, 3:219-231.
71. Goeders N.E., Kuhar M.J. Chronic cocaine administration induces opposite changes in dopamine receptors in the striatum and nucleus accumbens. Alcohol and Drug Research 1987, 7:207-216.
72. Gold L.H., Balster R.L. Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil. Psychopharmacology 1996, 126:286-292.
73. Gould R.W., Duke A.N., Nader M.A. PET studies in nonhuman primate models of cocaine abuse: Translational research related to vulnerability and neuroadaptations. Neuropharmacology 2013.
74. Gould R.W., Gage H.D., Banks M.L., Blaylock B.L., Czoty P.W., Nader M.A. Differential effects of cocaine and MDMA self-administration on cortical serotonin transporter availability in monkeys. Neuropharmacology 2011, 61:245-251.
75. Gould R.W., Gage H.D., Nader M.A. Effects of chronic cocaine self-administration on cognition and cerebral glucose utilization in Rhesus monkeys. Biological Psychiatry 2012, 72:856-863.
76. Grabowski J., Rhoades H., Elk R., Schmitz J., Davis C., Creson D., et al. Fluoxetine is ineffective for treatment of cocaine dependence or concurrent opiate and cocaine dependence: Two placebo-controlled double-blind trials. Journal of Clinical Psychopharmacology 1995, 15:163-174.
77. Grabowski J., Rhoades H., Schmitz J., Stotts A., Daruzska L.A., Creson D., et al. Dextroamphetamine for cocaine-dependence treatment: A double-blind randomized clinical trial. Journal of Clinical Psychopharmacology 2001, 21:522-526.
78. Grabowski J., Shearer J., Merrill J., Negus S.S. Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addictive Behaviors 2004, 29:1439-1464.
79. Grant S.J., Aston-Jones G., Redmond D.E. Responses of primate locus coeruleus neurons to simple and complex sensory stimuli. Brain Research Bulletin 1988, 21:401-410.
80. Greengard P. The neurobiology of dopamine signaling. Bioscience Reports 2001, 21:247-269.
81. Greenwald M.K., Lundahl L.H., Steinmiller C.L. Sustained release d-amphetamine reduces cocaine but not 'speedball'-seeking in buprenorphine-maintained volunteers: A test of dual-agonist pharmacotherapy for cocaine/heroin polydrug abusers. Neuropsychopharmacology 2010, 35:2624-2637.
82. Haney M., Spealman R. Controversies in translational research: Drug self-administration. Psychopharmacology 2008, 199:403-419.
83. Hart C.L., Haney M., Vosburg S.K., Rubin E., Foltin R.W. Smoked cocaine self-administration is decreased by modafinil. Neuropsychopharmacology 2008, 33:761-768.
84. Heal D.J., Buckley N.W., Gosden J., Slater N., France C.P., Hackett D. A preclinical evaluation of the discriminative and reinforcing properties of lisdexamfetamine in comparison to d-amfetamine, methylphenidate and modafinil. Neuropharmacology 2013, 73C:348-358.
85. Henry P.K., Murnane K.S., Votaw J.R., Howell L.L. Acute brain metabolic effects of cocaine in rhesus monkeys with a history of cocaine use. Brain Imaging and Behavior 2010, 4:212-219.
86. Hiranita T., Soto P.L., Newman A.H., Katz J.L. Assessment of reinforcing effects of benztropine analogs and their effects on cocaine self-administration in rats: Comparisons with monoamine uptake inhibitors. The Journal of Pharmacology and Experimental Therapeutics 2009, 329:677-686.
87. Hoffman B.J., Hansson S.R., Mezey E., Palkovits M. Localization and dynamic regulation of biogenic amine transporters in the mammalian central nervous system. Frontiers in Neuroendocrinology 1998, 19:187-231.
88. Howell L.L., Byrd L.D. Characterization of the effects of cocaine and GBR 12909, a dopamine uptake inhibitor, on behavior in the squirrel monkey. The Journal of Pharmacology and Experimental Therapeutics 1991, 258:178-185.
89. Howell L.L., Byrd L.D. Serotonergic modulation of the behavioral effects of cocaine in the squirrel monkey. The Journal of Pharmacology and Experimental Therapeutics 1995, 275:1551-1559.
90. Howell L.L., Carroll F.I., Votaw J.R., Goodman M.M., Kimmel H.L. Effects of combined dopamine and serotonin transporter inhibitors on cocaine self-administration in rhesus monkeys. The Journal of Pharmacology and Experimental Therapeutics 2007, 320:757-765.
91. Howell L.L., Czoty P.W., Byrd L.D. Pharmacological interactions between serotonin and dopamine on behavior in the squirrel monkey. Psychopharmacology 1997, 131:40-48.
92. Howell L.L., Czoty P.W., Kuhar M.J., Carrol F.I. Comparative behavioral pharmacology of cocaine and the selective dopamine uptake inhibitor RTI-113 in the squirrel monkey. The Journal of Pharmacology and Experimental Therapeutics 2000, 292:521-529.
93. Howell L.L., Hoffman J.M., Votaw J.R., Landrum A.M., Wilcox K.M., Lindsey K.P. Cocaine-induced brain activation determined by positron emission tomography neuroimaging in conscious rhesus monkeys. Psychopharmacology 2002, 159:154-160.
94. Howell L.L., Kimmel H.L. Monoamine transporters and psychostimulant addiction. Biochemical Pharmacology 2008, 75:196-217.
95. Howell L.L., Votaw J.R., Goodman M.M., Lindsey K.P. Cortical activation during cocaine use and extinction in rhesus monkeys. Psychopharmacology 2010, 208:191-199.
96. Howell L.L., Wilcox K.M. The dopamine transporter and cocaine medication development: Drug self-administration in nonhuman primates. The Journal of Pharmacology and Experimental Therapeutics 2001, 298:1-6.
97. Hoyer D., Hannon J.P., Martin G.R. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacology, Biochemistry and Behavior 2002, 71:533-554.
98. Huang C.C., Liang Y.C., Lee C.C., Wu M.Y., Hsu K.S. Repeated cocaine administration decreases 5-HT(2A) receptor-mediated serotonergic enhancement of synaptic activity in rat medial prefrontal cortex. Neuropsychopharmacology 2009, 34:1979-1992.
99. Jacobs B.L., Azmitia E.C. Structure and function of the brain serotonin system. Physiological Reviews 1992, 72:165-229.
100. Jacobsen L.K., Staley J.K., Malison R.T., Zoghbi S.S., Seibyl J.P., Kosten T.R., et al. Elevated central serotonin transporter binding availability in acutely abstinent cocaine-dependent patients. The American Journal of Psychiatry 2000, 157:1134-1140.
101. Jasinski D.R. An evaluation of the abuse potential of modafinil using methylphenidate as a reference. Journal of Psychopharmacology 2000, 14:53-60.
102. Johanson C.E., Fischman M.W. The pharmacology of cocaine related to its abuse. Pharmacological Reviews 1989, 41:3-52.
103. Johanson C.E., Frey K.A., Lundahl L.H., Keenan P., Lockhart N., Roll J., et al. Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers. Psychopharmacology 2006, 185:327-338.
104. Katz J.L. Drugs as reinforcers: Pharmacological and behavioural factors. The neuropharmacological basis of reward 1989, 164-213. Clarendon Press, Oxford. J.M. Liebman, S.J. Cooper (Eds.).
105. Katz J.L., Higgins S.T. The validity of the reinstatement model of craving and relapse to drug use. Psychopharmacology 2003, 168:21-30.
106. Katz J.L., Izenwasser S., Terry P. Relationships among dopamine transporter affinities and cocaine-like discriminative-stimulus effects. Psychopharmacology 2000, 148:90-98.
107. Kimmel H.L., Joyce A.R., Carroll F.I., Kuhar M.J. Dopamine D1 and D2 receptors influence dopamine transporter synthesis and degradation in the rat. The Journal of Pharmacology and Experimental Therapeutics 2001, 298:129-140.
108. Kimmel H.L., Negus S.S., Wilcox K.M., Ewing S.B., Stehouwer J., Goodman M.M., et al. Relationship between rate of drug uptake in brain and behavioral pharmacology of monoamine transporter inhibitors in rhesus monkeys. Pharmacology, Biochemistry and Behavior 2008, 90:453-462.
109. Kimmel H.L., O'Connor J.A., Carroll F.I., Howell L.L. Faster onset and dopamine transporter selectivity predict stimulant and reinforcing effects of cocaine analogs in squirrel monkeys. Pharmacology, Biochemistry and Behavior 2007, 86:45-54.
110. Kirkland Henry P., Davis M., Howell L.L. Effects of cocaine self-administration history under limited and extended access conditions on in vivo striatal dopamine neurochemistry and acoustic startle in rhesus monkeys. Psychopharmacology 2009, 205:237-247.
111. Kittler K., Lau T., Schloss P. Antagonists and substrates differentially regulate serotonin transporter cell surface expression in serotonergic neurons. European Journal of Pharmacology 2010, 629:63-67.
112. Kleven M.S., Anthony E.W., Woolverton W.L. Pharmacological characterization of the discriminative stimulus effects of cocaine in rhesus monkeys. The Journal of Pharmacology and Experimental Therapeutics 1990, 254:312-317.
113. Kleven M.S., Perry B.D., Woolverton W.L., Seiden L.S. Effects of repeated injections of cocaine on D1 and D2 dopamine receptors in rat brain. Brain Research 1990, 532:265-270.
114. Kleven M.S., Woolverton W.L. Effects of bromocriptine and desipramine on behavior maintained by cocaine or food presentation in rhesus monkeys. Psychopharmacology 1990, 101:208-213.
115. Kleven M.S., Woolverton W.L. Effects of three monoamine uptake inhibitors on behavior maintained by cocaine or food presentation in rhesus monkeys. Drug and Alcohol Dependence 1993, 31:149-158.
116. Kohut S.J., Fivel P.A., Blough B.E., Rothman R.B., Mello N.K. Effects of methcathinone and 3-Cl-methcathinone (PAL-434) in cocaine discrimination or self-administration in rhesus monkeys. The International Journal of Neuropsychopharmacology 2013, 16:1985-1998.
117. Koob G.F. Neural mechanisms of drug reinforcement. Annals of the New York Academy of Sciences 1992, 654:171-191.
118. Kuhar M.J., Pilotte N.S. Neurochemical changes in cocaine withdrawal. Trends in Pharmacological Sciences 1996, 17:260-264.
119. Langer S.Z., Galzin A.M. Studies on the serotonin transporter in platelets. Experientia 1988, 44:127-130.
120. Letchworth S.R., Daunais J.B., Hedgecock A.A., Porrino L.J. Effects of chronic cocaine administration on dopamine transporter mRNA and protein in the rat. Brain Research 1997, 750:214-222.
121. Letchworth S.R., Nader M.A., Smith H.R., Friedman D.P., Porrino L.J. Progression of changes in dopamine transporter binding site density as a result of cocaine self-administration in rhesus monkeys. The Journal of Neuroscience 2001, 21:2799-2807.
122. Letchworth S.R., Sexton T., Childers S.R., Vrana K.E., Vaughan R.A., Davies H.M., et al. Regulation of rat dopamine transporter mRNA and protein by chronic cocaine administration. Journal of Neurochemistry 1999, 73:1982-1989.
123. Levin F.R., Lehman A.F. Meta-analysis of desipramine as an adjunct in the treatment of cocaine addiction. Journal of Clinical Psychopharmacology 1991, 11:374-378.
124. Lile J., Nader M. The abuse liability and therapeutic potential of drugs evaluated for cocaine addiction as predicted by animal models. Current Neuropharmacology 2003, 1:21-46.
125. Lima M.S., Reisser A.A., Soares B.G., Farrell M. Antidepressants for cocaine dependence. Cochrane Database of Systematic Reviews 2003, CD002950.
126. Lin Z., Canales J.J., Bjorgvinsson T., Thomsen M., Qu H., Liu Q.R., et al. Monoamine transporters: Vulnerable and vital doorkeepers. Progress in Molecular Biology and Translational Science 2011, 98:1-46.
127. Lindsey K.P., Wilcox K.M., Votaw J.R., Goodman M.M., Plisson C., Carroll F.I., et al. Effects of dopamine transporter inhibitors on cocaine self-administration in rhesus monkeys: Relationship to transporter occupancy determined by positron emission tomography neuroimaging. The Journal of Pharmacology and Experimental Therapeutics 2004, 309:959-969.
128. Little K.Y., Elmer L.W., Zhong H., Scheys J.O., Zhang L. Cocaine induction of dopamine transporter trafficking to the plasma membrane. Molecular Pharmacology 2002, 61:436-445.
129. Little K.Y., Kirkman J.A., Carroll F.I., Clark T.B., Duncan G.E. Cocaine use increases [3H]WIN 35428 binding sites in human striatum. Brain Research 1993, 628:17-25.
130. Loder M.K., Melikian H.E. The dopamine transporter constitutively internalizes and recycles in a protein kinase C-regulated manner in stably transfected PC12 cell lines. The Journal of Biological Chemistry 2003, 278:22168-22174.
131. Malison R.T., Best S.E., van Dyck C.H., McCance E.F., Wallace E.A., Laruelle M., et al. Elevated striatal dopamine transporters during acute cocaine abstinence as measured by [123I] beta-CIT SPECT. The American Journal of Psychiatry 1998, 155:832-834.
132. Mariani J.J., Pavlicova M., Bisaga A., Nunes E.V., Brooks D.J., Levin F.R. Extended-release mixed amphetamine salts and topiramate for cocaine dependence: A randomized controlled trial. Biological Psychiatry 2012, 72:950-956.
133. Martinez D., Narendran R., Foltin R.W., Slifstein M., Hwang D.R., Broft A., et al. Amphetamine-induced dopamine release: Markedly blunted in cocaine dependence and predictive of the choice to self-administer cocaine. The American Journal of Psychiatry 2007, 164:622-629.
134. Martinez D., Slifstein M., Narendran R., Foltin R.W., Broft A., Hwang D.R., et al. Dopamine D1 receptors in cocaine dependence measured with PET and the choice to self-administer cocaine. Neuropsychopharmacology 2009, 34:1774-1782.
135. Martin-Fardon R., Weiss F. Modeling relapse in animals. Current Topics in Behavioral Neurosciences 2013, 13:403-432.
136. Mash D.C., Staley J.K., Izenwasser S., Basile M., Ruttenber A.J. Serotonin transporters upregulate with chronic cocaine use. Journal of Chemical Neuroanatomy 2000, 20:271-280.
137. Mateo Y., Lack C.M., Morgan D., Roberts D.C., Jones S.R. Reduced dopamine terminal function and insensitivity to cocaine following cocaine binge self-administration and deprivation. Neuropsychopharmacology 2005, 30:1455-1463.
138. McCann U.D., Kuwabara H., Kumar A., Palermo M., Abbey R., Brasic J., et al. Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users. Synapse 2008, 62:91-100.
139. McCann U.D., Szabo Z., Scheffel U., Dannals R.F., Ricaurte G.A. Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings. Lancet 1998, 352:1433-1437.
140. McClung J., Fantegrossi W., Howell L.L. Reinstatement of extinguished amphetamine self-administration by 3,4-methylenedioxymethamphetamine (MDMA) and its enantiomers in rhesus monkeys. Psychopharmacology 2010, 210:75-83.
141. Mello N.K., Lukas S.E., Bree M.P., Mendelson J.H. Desipramine effects on cocaine self-administration by rhesus monkeys. Drug and Alcohol Dependence 1990, 26:103-116.
142. Mello N.K., Negus S.S. Preclinical evaluation of pharmacotherapies for treatment of cocaine and opioid abuse using drug self-administration procedures. Neuropsychopharmacology 1996, 14:375-424.
143. Meltzer P.C., Liu S., Blanchette H., Blundell P., Madras B.K. Design and synthesis of an irreversible dopamine-sparing cocaine antagonist. Bioorganic & Medicinal Chemistry 2002, 10:3583-3591.
144. Moeller F.G., Schmitz J.M., Steinberg J.L., Green C.M., Reist C., Lai L.Y., et al. Citalopram combined with behavioral therapy reduces cocaine use: A double-blind, placebo-controlled trial. The American Journal of Drug and Alcohol Abuse 2007, 33:367-378.
145. Moeller F.G., Steinberg J.L., Schmitz J.M., Ma L., Liu S., Kjome K.L., et al. Working memory fMRI activation in cocaine-dependent subjects: Association with treatment response. Psychiatry Research 2010, 181:174-182.
146. Mooney M.E., Herin D.V., Schmitz J.M., Moukaddam N., Green C.E., Grabowski J. Effects of oral methamphetamine on cocaine use: A randomized, double-blind, placebo-controlled trial. Drug and Alcohol Dependence 2009, 101:34-41.
147. Moore R.J., Vinsant S.L., Nader M.A., Porrino L.J., Friedman D.P. Effect of cocaine self-administration on dopamine D2 receptors in rhesus monkeys. Synapse 1998, 30:88-96.
148. Moore R.J., Vinsant S.L., Nader M.A., Porrino L.J., Friedman D.P. Effect of cocaine self-administration on striatal dopamine D1 receptors in rhesus monkeys. Synapse 1998, 28:1-9.
149. Morgan D., Grant K.A., Gage H.D., Mach R.H., Kaplan J.R., Prioleau O., et al. Social dominance in monkeys: Dopamine D2 receptors and cocaine self-administration. Nature Neuroscience 2002, 5:169-174.
150. Murnane K.S., Howell L.L. Development of an apparatus and methodology for conducting functional magnetic resonance imaging (fMRI) with pharmacological stimuli in conscious rhesus monkeys. Journal of Neuroscience Methods 2010, 191:11-20.
151. Nader M.A., Daunais J.B., Moore T., Nader S.H., Moore R.J., Smith H.R., et al. Effects of cocaine self-administration on striatal dopamine systems in rhesus monkeys: Initial and chronic exposure. Neuropsychopharmacology 2002, 27:35-46.
152. Nader M.A., Grant K.A., Davies H.M., Mach R.H., Childers S.R. The reinforcing and discriminative stimulus effects of the novel cocaine analog 2beta-propanoyl-3beta-(4-tolyl)-tropane in rhesus monkeys. The Journal of Pharmacology and Experimental Therapeutics 1997, 280:541-550.
153. Nader M.A., Morgan D., Gage H.D., Nader S.H., Calhoun T.L., Buchheimer N., et al. PET imaging of dopamine D2 receptors during chronic cocaine self-administration in monkeys. Nature Neuroscience 2006, 9:1050-1056.
154. Nader M.A., Nader S.H., Czoty P.W., Riddick N.V., Gage H.D., Gould R.W., et al. Social dominance in female monkeys: Dopamine receptor function and cocaine reinforcement. Biological Psychiatry 2012, 72:414-421.
155. Natarajan R., Yamamoto B.K. The basal ganglia as a substrate for the multiple actions of amphetamines. Basal Ganglia 2011, 1:49-57.
156. Negus S.S. Rapid assessment of choice between cocaine and food in rhesus monkeys: Effects of environmental manipulations and treatment with d-amphetamine and flupenthixol. Neuropsychopharmacology 2003, 28:919-931.
157. Negus S.S., Banks M.L. Making the right choice: Lessons from drug discrimination for research on drug reinforcement and drug self-administration. Drug discrimination: Applications to medicinal chemistry and drug studies 2011, 361-388. John Wiley and Sons, Hoboken, NJ. R. Glennon, R. Young (Eds.).
158. Negus S.S., Baumann M.H., Rothman R.B., Mello N.K., Blough B.E. Selective suppression of cocaine- versus food-maintained responding by monoamine releasers in rhesus monkeys: Benzylpiperazine, (+)phenmetrazine, and 4-benzylpiperidine. The Journal of Pharmacology and Experimental Therapeutics 2009, 329:272-281.
159. Negus S.S., Brandt M.R., Mello N.K. Effects of the long-acting monoamine reuptake inhibitor indatraline on cocaine self-administration in rhesus monkeys. The Journal of Pharmacology and Experimental Therapeutics 1999, 291:60-69.
160. Negus S.S., Mello N.K. Effects of mu-opioid agonists on cocaine- and food-maintained responding and cocaine discrimination in rhesus monkeys: Role of mu-agonist efficacy. The Journal of Pharmacology and Experimental Therapeutics 2002, 300:1111-1121.
161. Negus S.S., Mello N.K. Effects of chronic d-amphetamine treatment on cocaine- and food-maintained responding under a progressive-ratio schedule in rhesus monkeys. Psychopharmacology 2003, 167:324-332.
162. Negus S.S., Mello N.K. Effects of chronic d-amphetamine treatment on cocaine- and food-maintained responding under a second-order schedule in rhesus monkeys. Drug and Alcohol Dependence 2003, 70:39-52.
163. Negus S.S., Mello N.K. Effects of chronic methadone treatment on cocaine- and food-maintained responding under second-order, progressive-ratio and concurrent-choice schedules in rhesus monkeys. Drug and Alcohol Dependence 2004, 74:297-309.
164. Negus S.S., Mello N.K., Blough B.E., Baumann M.H., Rothman R.B. Monoamine releasers with varying selectivity for dopamine/norepinephrine versus serotonin release as candidate "agonist" medications for cocaine dependence: Studies in assays of cocaine discrimination and cocaine self-administration in rhesus monkeys. The Journal of Pharmacology and Experimental Therapeutics 2007, 320:627-636.
165. Negus S.S., Mello N.K., Kimmel H.L., Howell L.L., Carroll F.I. Effects of the monoamine uptake inhibitors RTI-112 and RTI-113 on cocaine- and food-maintained responding in rhesus monkeys. Pharmacology, Biochemistry and Behavior 2009, 91:333-338.
166. Negus S.S., Mello N.K., Lamas X., Mendelson J.H. Acute and chronic effects of flupenthixol on the discriminative stimulus and reinforcing effects of cocaine in rhesus monkeys. The Journal of Pharmacology and Experimental Therapeutics 1996, 278:879-890.
167. Negus S.S., Mello N.K., Portoghese P.S., Lin C.E. Effects of kappa opioids on cocaine self-administration by rhesus monkeys. The Journal of Pharmacology and Experimental Therapeutics 1997, 282:44-55.
168. Newman J.L., Negus S.S., Lozama A., Prisinzano T.E., Mello N.K. Behavioral evaluation of modafinil and the abuse-related effects of cocaine in rhesus monkeys. Experimental and Clinical Psychopharmacology 2010, 18:395-408.
169. Norman A.B., Norman M.K., Hall J.F., Tsibulsky V.L. Priming threshold: A novel quantitative measure of the reinstatement of cocaine self-administration. Brain Research 1999, 831:165-174.
170. O'Brien C.P. Drug addiction and drug abuse. Goodman and Gilman's The pharmacological basis of therapeutics 2006, 607-628. McGraw-Hill, New York. L. Brunton, J. Lazo, K. Parker (Eds.).
171. Oliveto A., Poling J., Mancino M.J., Williams D.K., Thostenson J., Pruzinsky R., et al. Sertraline delays relapse in recently abstinent cocaine-dependent patients with depressive symptoms. Addiction 2012, 107:131-141.
172. Overton D.A. Applications and limitations of the drug discrimination method for the study of drug abuse. Methods of assessing the reinforcing properties of abused drugs 1987, 291-340. Springer Verlag, New York. M.J. Bozarth (Ed.).
173. Peltier R.L., Li D.H., Lytle D., Taylor C.M., Emmett-Oglesby M.W. Chronic d-amphetamine or methamphetamine produces cross-tolerance to the discriminative and reinforcing stimulus effects of cocaine. The Journal of Pharmacology and Experimental Therapeutics 1996, 277:212-218.
174. Pilotte N.S., Sharpe L.G., Kuhar M.J. Withdrawal of repeated intravenous infusions of cocaine persistently reduces binding to dopamine transporters in the nucleus accumbens of Lewis rats. The Journal of Pharmacology and Experimental Therapeutics 1994, 269:963-969.
175. Platt D.M., Rowlett J.K., Spealman R.D. Noradrenergic mechanisms in cocaine-induced reinstatement of drug seeking in squirrel monkeys. The Journal of Pharmacology and Experimental Therapeutics 2007, 322:894-902.
176. Preston K.L., Sullivan J.T., Berger P., Bigelow G.E. Effects of cocaine alone and in combination with mazindol in human cocaine abusers. The Journal of Pharmacology and Experimental Therapeutics 1993, 267:296-307.
177. Reivich M., Alavi A., Wolf A., Fowler J., Russell J., Arnett C., et al. Glucose metabolic rate kinetic model parameter determination in humans: The lumped constants and rate constants for [18F]fluorodeoxyglucose and [11C]deoxyglucose. Journal of Cerebral Blood Flow and Metabolism 1985, 5:179-192.
178. Ricci L.A., Stellar J.R., Todtenkopf M.S. Subregion-specific down-regulation of 5-HT3 immunoreactivity in the nucleus accumbens shell during the induction of cocaine sensitization. Pharmacology, Biochemistry and Behavior 2004, 77:415-422.
179. Ritz M.C., Kuhar M.J. Relationship between self-administration of amphetamine and monoamine receptors in brain: Comparison with cocaine. The Journal of Pharmacology and Experimental Therapeutics 1989, 248:1010-1017.
180. Ritz M.C., Lamb R.J., Goldberg S.R., Kuhar M.J. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 1987, 237:1219-1223.
181. Robinson T.E., Berridge K.C. The psychology and neurobiology of addiction: An incentive-sensitization view. Addiction 2000, 95(Suppl. 2):S91-S117.
182. Rothman R.B., Baumann M.H., Dersch C.M., Romero D.V., Rice K.C., Carroll F.I., et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 2001, 39:32-41.
183. Rothman R.B., Becketts K.M., Radesca L.R., de Costa B.R., Rice K.C., Carroll F.I., et al. Studies of the biogenic amine transporters. II. A brief study on the use of [3H]DA-uptake-inhibition to transporter-binding-inhibition ratios for the in vitro evaluation of putative cocaine antagonists. Life Sciences 1993, 53:L267-L272.
184. Rothman R.B., Blough B.E., Baumann M.H. Appetite suppressants as agonist substitution therapies for stimulant dependence. Annals of the New York Academy of Sciences 2002, 965:109-126.
185. Rothman R.B., Blough B.E., Baumann M.H. Dual dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions. The AAPS Journal 2007, 9:E1-E10.
186. Rothman R.B., Blough B.E., Baumann M.H. Dual dopamine/serotonin releasers: Potential treatment agents for stimulant addiction. Experimental and Clinical Psychopharmacology 2008, 16:458-474.
187. Rothman R.B., Blough B.E., Woolverton W.L., Anderson K.G., Negus S.S., Mello N.K., et al. Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration. The Journal of Pharmacology and Experimental Therapeutics 2005, 313:1361-1369.
188. Rothman R.B., Clark R.D., Partilla J.S., Baumann M.H. (+)-Fenfluramine and its major metabolite, (+)-norfenfluramine, are potent substrates for norepinephrine transporters. The Journal of Pharmacology and Experimental Therapeutics 2003, 305:1191-1199.
189. Rothman R.B., Dersch C.M., Ananthan S., Partilla J.S. Studies of the biogenic amine transporters. 13. Identification of "agonist" and "antagonist" allosteric modulators of amphetamine-induced dopamine release. The Journal of Pharmacology and Experimental Therapeutics 2009, 329:718-728.
190. Rothman R.B., Glowa J.R. A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development. Focus on GBR 12909. Molecular Neurobiology 1995, 11:1-19.
191. Rothman R.B., Katsnelson M., Vu N., Partilla J.S., Dersch C.M., Blough B.E., et al. Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. European Journal of Pharmacology 2002, 447:51-57.
192. Rudnick G. Mechanisms of biogenic amine transporters. Neurotransmitter transporters: Structure, function, and regulation 1997, 73-100. Humana Press, Totowa, NY. M. Reith (Ed.).
193. Rudnick G., Clark J. From synapse to vesicle: The reuptake and storage of biogenic amine neurotransmitters. Biochimica et Biophysica Acta 1993, 1144:249-263.
194. Rush C.R., Stoops W.W., Sevak R.J., Hays L.R. Cocaine choice in humans during D-amphetamine maintenance. Journal of Clinical Psychopharmacology 2010, 30:152-159.
195. Sawyer E.K., Mun J., Nye J.A., Kimmel H.L., Voll R.J., Stehouwer J.S., et al. Neurobiological changes mediating the effects of chronic fluoxetine on cocaine use. Neuropsychopharmacology 2012, 37:1816-1824.
196. Schama K.F., Howell L.L., Byrd L.D. Serotonergic modulation of the discriminative-stimulus effects of cocaine in squirrel monkeys. Psychopharmacology 1997, 132:27-34.
197. Schechter M.D. Rats become acutely tolerant to cathine after amphetamine or cathinone administration. Psychopharmacology 1990, 101:126-131.
198. Schenk S., Hely L., Gittings D., Lake B., Daniela E. Effects of priming injections of MDMA and cocaine on reinstatement of MDMA- and cocaine-seeking in rats. Drug and Alcohol Dependence 2008, 96:249-255.
199. Schenk S., Partridge B. Cocaine-seeking produced by experimenter-administered drug injections: Dose-effect relationships in rats. Psychopharmacology 1999, 147:285-290.
200. Schindler C.W., Panlilio L.V., Thorndike E.B. Effect of rate of delivery of intravenous cocaine on self-administration in rats. Pharmacology, Biochemistry and Behavior 2009, 93:375-381.
201. Schmitz J.M., Averill P., Stotts A.L., Moeller F.G., Rhoades H.M., Grabowski J. Fluoxetine treatment of cocaine-dependent patients with major depressive disorder. Drug and Alcohol Dependence 2001, 63:207-214.
202. Schuldiner S., Shirvan A., Linial M. Vesicular neurotransmitter transporters: From bacteria to humans. Physiological Reviews 1995, 75:369-392.
203. Schuster C.R., Johanson C.E. Relationship between the discriminative stimulus properties and subjective effects of drugs. Psychopharmacology Series 1988, 4:161-175.
204. Sekine Y., Iyo M., Ouchi Y., Matsunaga T., Tsukada H., Okada H., et al. Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. The American Journal of Psychiatry 2001, 158:1206-1214.
205. Shaham Y., Shalev U., Lu L., De Wit H., Stewart J. The reinstatement model of drug relapse: History, methodology and major findings. Psychopharmacology 2003, 168:3-20.
206. Skinner B.F. The behavior of organisms 1938, Appleton-Century-Crofts, New York.
207. Spealman R.D. Modification of behavioral effects of cocaine by selective serotonin and dopamine uptake inhibitors in squirrel monkeys. Psychopharmacology 1993, 112:93-99.
208. Spealman R.D. Noradrenergic involvement in the discriminative stimulus effects of cocaine in squirrel monkeys. The Journal of Pharmacology and Experimental Therapeutics 1995, 275:53-62.
209. Spealman R.D., Barrett-Larimore R.L., Rowlett J.K., Platt D.M., Khroyan T.V. Pharmacological and environmental determinants of relapse to cocaine-seeking behavior. Pharmacology, Biochemistry and Behavior 1999, 64:327-336.
210. Staley J.K., Hearn W.L., Ruttenber A.J., Wetli C.V., Mash D.C. High affinity cocaine recognition sites on the dopamine transporter are elevated in fatal cocaine overdose victims. The Journal of Pharmacology and Experimental Therapeutics 1994, 271:1678-1685.
211. Stine S.M., Krystal J.H., Kosten T.R., Charney D.S. Mazindol treatment for cocaine dependence. Drug and Alcohol Dependence 1995, 39:245-252.
212. Stoops W.W., Rush C.R. Agonist replacement for stimulant dependence: A review of clinical research. Current Pharmaceutical Design 2013.
213. Tella S.R. Effects of monoamine reuptake inhibitors on cocaine self-administration in rats. Pharmacology, Biochemistry and Behavior 1995, 51:687-692.
214. Tella S.R., Ladenheim B., Andrews A.M., Goldberg S.R., Cadet J.L. Differential reinforcing effects of cocaine and GBR-12909: Biochemical evidence for divergent neuroadaptive changes in the mesolimbic dopaminergic system. The Journal of Neuroscience 1996, 16:7416-7427.
215. Thomsen M., Barrett A.C., Negus S.S., Caine S.B. Cocaine versus food choice procedure in rats: Environmental manipulations and effects of amphetamine. Journal of the Experimental Analysis of Behavior 2013, 99:211-233.
216. Thomsen M., Hall F.S., Uhl G.R., Caine S.B. Dramatically decreased cocaine self-administration in dopamine but not serotonin transporter knock-out mice. The Journal of Neuroscience 2009, 29:1087-1092.
217. Thomsen M., Han D.D., Gu H.H., Caine S.B. Lack of cocaine self-administration in mice expressing a cocaine-insensitive dopamine transporter. The Journal of Pharmacology and Experimental Therapeutics 2009, 331:204-211.
218. Vanover K.E., Nader M.A., Woolverton W.L. Evaluation of the discriminative stimulus and reinforcing effects of sertraline in rhesus monkeys. Pharmacology, Biochemistry and Behavior 1992, 41:789-793.
219. Vocci F.J., Appel N.M. Approaches to the development of medications for the treatment of methamphetamine dependence. Addiction 2007, 102(Suppl. 1):96-106.
220. Volkow N.D., Chang L., Wang G.J., Fowler J.S., Ding Y.S., Sedler M., et al. Low level of brain dopamine D2 receptors in methamphetamine abusers: Association with metabolism in the orbitofrontal cortex. The American Journal of Psychiatry 2001, 158:2015-2021.
221. Volkow N.D., Chang L., Wang G.J., Fowler J.S., Franceschi D., Sedler M., et al. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. The Journal of Neuroscience 2001, 21:9414-9418.
222. Volkow N.D., Chang L., Wang G.J., Fowler J.S., Franceschi D., Sedler M.J., et al. Higher cortical and lower subcortical metabolism in detoxified methamphetamine abusers. The American Journal of Psychiatry 2001, 158:383-389.
223. Volkow N.D., Chang L., Wang G.J., Fowler J.S., Leonido-Yee M., Franceschi D., et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. The American Journal of Psychiatry 2001, 158:377-382.
224. Volkow N.D., Fowler J.S. Addiction, a disease of compulsion and drive: Involvement of the orbitofrontal cortex. Cerebral Cortex 2000, 10:318-325.
225. Volkow N.D., Fowler J.S., Logan J., Alexoff D., Zhu W., Telang F., et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: Clinical implications. JAMA 2009, 301:1148-1154.
226. Volkow N.D., Fowler J.S., Wang G.J., Swanson J.M. Dopamine in drug abuse and addiction: Results from imaging studies and treatment implications. Molecular Psychiatry 2004, 9:557-569.
227. Volkow N.D., Fowler J.S., Wolf A.P., Hitzemann R., Dewey S., Bendriem B., et al. Changes in brain glucose metabolism in cocaine dependence and withdrawal. The American Journal of Psychiatry 1991, 148:621-626.
228. Volkow N.D., Mullani N., Gould K.L., Adler S., Krajewski K. Cerebral blood flow in chronic cocaine users: A study with positron emission tomography. The British Journal of Psychiatry 1988, 152:641-648.
229. Volkow N.D., Wang G.J., Fischman M.W., Foltin R.W., Fowler J.S., Abumrad N.N., et al. Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature 1997, 386:827-830.
230. Volkow N.D., Wang G.J., Fowler J.S., Logan J., Angrist B., Hitzemann R., et al. Effects of methylphenidate on regional brain glucose metabolism in humans: Relationship to dopamine D2 receptors. The American Journal of Psychiatry 1997, 154:50-55.
231. Vosburg S.K., Hart C.L., Haney M., Rubin E., Foltin R.W. Modafinil does not serve as a reinforcer in cocaine abusers. Drug and Alcohol Dependence 2010, 106:233-236.
232. Votaw J.R., Howell L.L., Martarello L., Hoffman J.M., Kilts C.D., Lindsey K.P., et al. Measurement of dopamine transporter occupancy for multiple injections of cocaine using a single injection of [F-18]FECNT. Synapse 2002, 44:203-210.
233. Walsh S.L., Middleton L.S., Wong C.J., Nuzzo P.A., Campbell C.L., Rush C.R., et al. Atomoxetine does not alter cocaine use in cocaine dependent individuals: Double blind randomized trial. Drug and Alcohol Dependence 2013, 130:150-157.
234. Walsh S.L., Preston K.L., Sullivan J.T., Fromme R., Bigelow G.E. Fluoxetine alters the effects of intravenous cocaine in humans. Journal of Clinical Psychopharmacology 1994, 14:396-407.
235. Wee S., Anderson K.G., Baumann M.H., Rothman R.B., Blough B.E., Woolverton W.L. Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs. The Journal of Pharmacology and Experimental Therapeutics 2005, 313:848-854.
236. Westerink R.H. Targeting exocytosis: Ins and outs of the modulation of quantal dopamine release. CNS & Neurological Disorders Drug Targets 2006, 5:57-77.
237. Wilcox K.M., Kimmel H.L., Lindsey K.P., Votaw J.R., Goodman M.M., Howell L.L. In vivo comparison of the reinforcing and dopamine transporter effects of local anesthetics in rhesus monkeys. Synapse 2005, 58:220-228.
238. Wilcox K.M., Lindsey K.P., Votaw J.R., Goodman M.M., Martarello L., Carroll F.I., et al. Self-administration of cocaine and the cocaine analog RTI-113: Relationship to dopamine transporter occupancy determined by PET neuroimaging in rhesus monkeys. Synapse 2002, 43:78-85.
239. Wilson J.M., Nobrega J.N., Corrigall W.A., Coen K.M., Shannak K., Kish S.J. Amygdala dopamine levels are markedly elevated after self- but not passive-administration of cocaine. Brain Research 1994, 668:39-45.
240. Wimalasena K. Vesicular monoamine transporters: Structure-function, pharmacology, and medicinal chemistry. Medicinal Research Reviews 2011, 31:483-519.
241. Winstanley E.L., Bigelow G.E., Silverman K., Johnson R.E., Strain E.C. A randomized controlled trial of fluoxetine in the treatment of cocaine dependence among methadone-maintained patients. Journal of Substance Abuse Treatment 2011, 40:255-264.
242. Wojnicki F.H., Rothman R.B., Rice K.C., Glowa J.R. Effects of phentermine on responding maintained under multiple fixed-ratio schedules of food and cocaine presentation in the rhesus monkey. The Journal of Pharmacology and Experimental Therapeutics 1999, 288:550-560.
243. Wolf M.E., Sun X., Mangiavacchi S., Chao S.Z. Psychomotor stimulants and neuronal plasticity. Neuropharmacology 2004, 47(Suppl. 1):61-79.
244. Woolverton W.L. Evaluation of the role of norepinephrine in the reinforcing effects of psychomotor stimulants in rhesus monkeys. Pharmacology, Biochemistry and Behavior 1987, 26:835-839.
245. Woolverton W.L., Cervo L., Johanson C.E. Effects of repeated methamphetamine administration on methamphetamine self-administration in rhesus monkeys. Pharmacology, Biochemistry and Behavior 1984, 21:737-741.
246. Woolverton W.L., Johnson K.M. Neurobiology of cocaine abuse. Trends in Pharmacological Sciences 1992, 13:193-200.
247. Woolverton W.L., Weiss S.R.B. Tolerance and sensitization to cocaine: An integrated view. Cocaine abuse: Behavior, pharmacology, and clinical applications 1998, 107-134. Academic Press, San Diego. S. Higgens, J. Katz (Eds.).
248. Young A.M., Herling S. Drugs as reinforcers: Studies in laboratory animals. Behavioral analysis of drug dependence 1986, 9-67. Academic Press, Orlando, FL. S.R. Goldberg, I.P. Stolerman (Eds.).
249. Zolkowska D., Jain R., Rothman R.B., Partilla J.S., Roth B.L., Setola V., et al. Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil. The Journal of Pharmacology and Experimental Therapeutics 2009, 329:738-746.